Suppr超能文献

术前生物药物对原发性回肠储袋肛管吻合术后并发症及功能的影响:系统评价与荟萃分析

Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis.

作者信息

Selvaggi Francesco, Pellino Gianluca, Canonico Silvestro, Sciaudone Guido

机构信息

Unit of General Surgery, Second University of Naples, Naples, Italy.

出版信息

Inflamm Bowel Dis. 2015 Jan;21(1):79-92. doi: 10.1097/MIB.0000000000000232.

Abstract

BACKGROUND

Debate exists concerning the presumed risk of postoperative complications in patients with ulcerative colitis (UC) receiving preoperative infliximab (IFX). Meta-analyses are contrasting because of many confounders included into analysis. Our aim was to determine the impact of IFX on pouch-related postoperative complications in patients with UC undergoing surgery with primary ileal pouch-anal anastomosis.

METHODS

We performed a systematic review to identify studies comparing the outcomes of patients undergoing surgery for UC with or without previous IFX exposure. The primary end points were (1) early ileal pouch-anal anastomosis-related complications after surgery with primary pouch formation and (2) those occurring after ileostomy closure. Secondary end points were the effects of IFX on total, infectious, and noninfectious complications in patients with UC undergoing any type of surgery. Results are reported as pooled odds ratio (OR) with 95% confidence intervals (CIs).

RESULTS

Seven papers, including 162 patients receiving biologics and 468 controls all undergoing primary pouch formation, were included for the primary aim. Patients receiving IFX were more likely developing early (OR = 4.12; 95% CI, 2.37-7.15; P < 0.001) and post-ileostomy closure (OR = 2.27; 95% CI, 1.27-4.05; P = 0.005) ileal pouch-anal anastomosis-related complications. Number needed to harm was calculated to be 5 and 4, respectively. Having received at least 3 IFX effusions increased the risk of early complications (OR = 9.59; 95% CI, 2.92-31.44; P = 0.0002), whereas an interval of <12 weeks since last effusion did not (OR = 2.35; 95% CI, 0.98-5.64; P = 0.06). Meta-analyses of 14 studies reporting on any type of surgery found that IFX showed a trend toward higher total and infectious complications, but no significant differences were observed. Biologics were associated with lower surgical site infection (OR = 0.67; 95% CI, 0.45-0.99; P = 0.04).

CONCLUSIONS

IFX exposure increases early pouch-specific complications and complications after ileostomy closure in UC. Avoiding primary pouch formation could be a prudent approach.

摘要

背景

对于接受术前英夫利昔单抗(IFX)治疗的溃疡性结肠炎(UC)患者术后并发症的假定风险存在争议。由于分析中纳入了许多混杂因素,荟萃分析结果相互矛盾。我们的目的是确定IFX对接受原发性回肠袋肛管吻合术的UC患者与袋相关的术后并发症的影响。

方法

我们进行了一项系统评价,以确定比较有或没有IFX暴露史的UC手术患者结局的研究。主要终点是:(1)原发性袋形成手术后早期回肠袋肛管吻合术相关并发症,以及(2)回肠造口关闭后发生的并发症。次要终点是IFX对接受任何类型手术的UC患者的总并发症、感染性并发症和非感染性并发症的影响。结果以合并比值比(OR)及95%置信区间(CI)表示。

结果

纳入七篇论文,其中162例接受生物制剂治疗的患者和468例均接受原发性袋形成的对照患者用于主要目的分析。接受IFX治疗的患者更有可能发生早期(OR = 4.12;95%CI,2.37 - 7.15;P < 0.001)和回肠造口关闭后(OR = 2.27;95%CI,1.27 - 4.05;P = 0.005)的回肠袋肛管吻合术相关并发症。危害所需治疗人数分别计算为5和4。接受至少3次IFX输注会增加早期并发症的风险(OR = 9.59;95%CI,2.92 - 31.44;P = 0.0002),而自上次输注以来间隔<12周则不会(OR = 2.35;95%CI,0.98 - 5.64;P = 0.06)。对14项报告任何类型手术的研究进行的荟萃分析发现,IFX有使总并发症和感染性并发症增加的趋势,但未观察到显著差异。生物制剂与较低的手术部位感染相关(OR = 0.67;95%CI,0.45 - 0.99;P = 0.04)。

结论

暴露于IFX会增加UC患者早期特定于袋的并发症以及回肠造口关闭后的并发症。避免原发性袋形成可能是一种谨慎的做法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验